Biotech Values

[genisi]

I think ß-secretase inhibitors therapies will face similar challenges to those seen with y-secretase (because the enzyme has many substrates* and a wide substrate binding domain) I'd expect serious off-target tox.

*like neuregulin-1, which is involved in myelination and y-secretase inhibitors have in fact shown AE on myelin in animal models.